Preliminary results of pinpoint plantar long-wavelength infrared light irradiation on blood glucose, insulin and stress hormones in patients with type 2 diabetes mellitus

Kenji Ryotokuji 1, Keisou Ishimaru 1, Kazuhiko Kihara 1, Yoshihisa Namiki 1, Nobumichi Hozumi 1

1: Faculty of Health Sciences, Ryotokuji University, Urayasu, Japan

Background and aims: This study was aimed at the development of a novel noninvasive treatment system, “pinpoint plantar long-wavelength infrared light irradiation (PP-LILI)”, which may be able to relieve mental stress and normalize blood glucose level via the reduction of stress hormones in type 2 (non-insulin-dependent) diabetes mellitus (DM) patients. Materials (Subjects) and methods: Based on this hypothesis, the present study was undertaken to examine effects of PP-LILI on stress hormones (ACTH and cortisol), blood glucose, HbA1c, and insulin levels in 10 patients with type 2 DM. Each patient received PP-LILI of the foot for 15 minutes once weekly using a stress free apparatus (infrared wavelength, 9,000-12,000 nm/power 30 mW).

Results: In response to this therapy, ACTH (P<0.01) and cortisol (P<0.05) levels decreased significantly. Fasting blood glucose (P<0.05) and insulin (P<0.05) levels also decreased significantly along with a tendency for HbA1c to decrease.

Conclusions: The present data raise the possibility that PP-LILI can normalize blood glucose levels by reducing stress hormones such as cortisol, which aggravate DM, and by improving insulin sensitivity, thereby contributing to prevention and treatment of DM.

Key words: Pinpoint plantar long-wavelength infrared light irradiation (PP-LILI) • relieving stress • type 2 (non-insulin-dependent) diabetes mellitus (DM) • blood glucose • stress hormones.
not yet been achieved. As blood glucose elevation and cortisol secretion are closely related, this study was conducted to investigate clinical responses to PP-LILI Stress Free Therapy® in terms of the effects of this therapy on blood glucose, glycosylated hemoglobin (HbA1c), insulin, and stress hormones (ACTH and cortisol) in patients with type 2 DM.

**Subjects and Methods**

The study was conducted on 10 patients with type 2 DM (6 men and 4 women; mean age, 62.0 ± 7.7 years) whose glycemic control was not achieved despite taking oral anti-diabetic medications. Each patient received PP-LILI of the center of the area between the epiphyses of the second and third metatarsophalangeal joints of the foot for 15 minutes once weekly over an average 4-week period using a stress free apparatus (Controlled Medical Device Approval No. 224AFBZX00075000; probe diameter, 20 mm; infrared wavelength, 9,000-12,000 nm/power 30 mW) after a 15-minute rest in the supine position at each session (Fig. 1). The oral anti-diabetic medications were continued during the PP-LILI therapy period.

For assays of blood glucose, HbA1c, insulin, and stress markers (ACTH and cortisol), 3 mL of blood were drawn through the cubital vein before and after PP-LILI, centrifuged (at 1200 g, 5 min), and analyzed for ACTH by chemiluminescent immunoassay (CLIA), for cortisol by electrochemiluminescence immunoassay (ECLIA), for glucose by the standard enzymatic method, for HbA1c by latex agglutination-turbidimetric immunoassay, and for insulin by CLIA. All blood sampling was carried out under identical conditions in view of the influence of such factors as assay time period and circadian rhythm.

This study was conducted after review and approval by the Ethics Committee of Ryotokuji University. Written informed consent was obtained from each patient after a full explanation of the nature and aims of the study.

Statistical evaluation of the data was performed using the sign test and paired *t*-test, with *p*-values of less than 0.05 considered to be significant.

**Results**

**Changes in blood glucose and insulin levels**

We examined blood glucose changes following PP-LILI and found that the blood glucose level decreased significantly from a pre-treatment value of 153.6±107.8 mg/dL to 96.2±11.8 mg/dL after treatment (*P*<0.05) (Fig. 2). The serum insulin level was 31.1±27.1 µU/mL.
before treatment and decreased significantly to 10.8±10.9 µU/mL after treatment (P<0.05) (Fig. 3).

Then we measured HbA1c (NGSP: National Glycohemoglobin Standardization Program). HbA1c levels decreased from a pre-treatment value of 6.9±2.6% to a post-treatment value of 5.8±0.4%, and HbA1c (JDS: Japan Diabetes Society) from a pre-treatment value of 6.6±2.6% to a post-treatment value of 5.6±0.4%; hence, both parameters showed a tendency to drop in parallel with the insulin level decrease (Figs. 4).

**Stress hormone changes**

The results on the HbA1c and blood glucose levels reveal that PP-LILI is effective to improve these values. Next, we have investigated the effects of PP-LILI on the changes in stress hormone levels. Cortisol secretion decreased significantly to 8.4±3.5 µg/dL after treatment, compared to 11.6±2.9 µg/dL before treatment (P<0.05) (Fig. 5). ACTH secretion was also reduced from a pre-

**Figure 2:** Improvement of the value of blood glucose after the PP-LILI.

**Figure 3:** Improvement of the value of insulin after the PP-LILI.

**Figure 4:** Changes of the value of HbA1c after the PP-LILI.

**Figure 5:** Improvement of the value of cortisol after the PP-LILI.
treatment value of 29.6±21.9 pg/mL to 14.5±8.6 pg/mL after treatment (P<0.01) (Fig. 6).

Discussion

We have reported, for the first time, the efficacy of PP-LILI for elevating peripheral deep-body temperature and stabilizing blood pressure as well as for significantly reducing secretions of such stress hormones as ACTH and cortisol, and that of amylase, and we have been applying PP-LILI as Stress Free Therapy® in our daily clinical practice setting.1)

It is universally recognized that psychological stress stimulates the sympathetic nervous system via the brain and central nervous system to constrict blood vessels and lower deep body temperature, and also stimulates the hypothalamus (paraventricular nucleus) triggering release of corticotropin releasing hormone, that ACTH is thereby secreted from the anterior pituitary lobe and stimulates cortisol secretion from the adrenal cortex.5,6)

The relationship of stress to DM has recently been receiving considerable attention. Type 2 DM is ascribed primarily to the following two factors: insufficient insulin secretion and tissue hyposensitivity to this hormone. These factors account for more than 90% of all DM cases in Japan. Furthermore, DM as a lifestyle-related disease is usually of this type. As regards the relationships between type 2 DM and hormones, secretions of cortisol and ACTH are known to be associated with complications. 7) Analysis of data from 170 type 2 DM cases revealed a positive correlation of cortisol secretion with the development of complications of DM.8,9) Based on these reports, we explored the clinical feasibility of reducing blood glucose and stress hormone levels in patients with type 2 DM through the stress-relieving effects of PP-LILI. In response to this irradiation, blood glucose dropped significantly from a pre-treatment level of 153.6±107.8 mg/dL to a post-treatment level of 96.2±11.8 mg/dL (P<0.05). Although patients with a serum insulin level 15.0 µU/mL would obviously be insulin-resistant, the present series exhibited a significant decrease in the serum insulin level from a pre-treatment value of 31.1±27.1 µU/mL to 10.8±10.9 µU/mL after treatment (P<0.05), demonstrating that PP-LILI is highly likely to contribute to amelioration of insulin resistance.

The long-term marker of blood glucose control HbA1c tended to decrease, though the decrement did not reach statistical significance, in response to the PP-LILI. Our present findings, i.e., favorable glycemic control with repeated or intermittent PP-LILI, make this a promising treatment strategy and we plan to assess this therapeutic effect in the near future. As for stress markers, there was a significant decrease in serum cortisol from a pre-treatment level of 11.6±2.9 µg/dL to a post-treatment level of 8.4±3.5 µg/dL (P<0.05). Serum ACTH also decreased significantly from a pre-treatment level of 29.6±21.9 pg/mL to a post-treatment level of 14.5±8.6 pg/mL (P<0.01). Many reports have documented that hypothalamic-pituitary-adrenal axis in stress signaling is related to DM.7-9) Therefore, it would not be unreasonable to assume that PP-LILI, which has been proven to reduce serum levels of adrenal glucocorticoid hormones, contributes to the suppression of blood glucose elevation and thereby improves insulin resistance in patients with type 2 DM.

Attention has been focused in recent years on the major involvement of AMP-activated protein kinase (AMPK) in systemic metabolic regulation of carbohydrates and lipids. This enzyme expressed in the cells of various tissues, is activated in response to a decrease in ATP level and depresses ATP consumption, thereby regulating various metabolic pathways in a direction favoring increased ATP production. Several studies have explored the possibility that the gene encoding adiponectin is involved in the enhancement of insulin sensitivity via activation of hepatic AMPK, thereby possibly improving the relative insulin insensitivity in type 2 DM.10,11) Adiponectin has recently been attracting attention as a beneficial substance of adipocytic origin. It exerts diverse physiological effects. Perhaps most significantly, it has been demonstrated that the insulin resistance-improving effect of adiponectin is attributable to activities including inhibition of enhanced fatty acid oxidation and of gluconeogenesis in the liver, facilitation of fatty acid oxidation and of glucose metabolism, etc.
uptake in skeletal muscles, and inhibition of tumor necrosis factor-α (TNF-α) production in adipose tissues. It has also been shown that adiponectin levels are low in patients with DM. In the present study as well, we quantified the expression level the adiponectin gene using the microarray method before and after the PP-LILI therapy and these assays demonstrated a significant post-treatment increase in adiponectin receptor 2 (Adip R 2) expression (data not shown), along with a decrease in blood glucose to 101 mg/dL in a patient whose pre-treatment blood glucose level was 435mg/dL. Adip R 2 is known to facilitate fatty acid decomposition in the liver, and the preset results suggest that PP-LILI may act on adiponectin receptors, thereby accelerating fat combustion and improving insulin resistance.

A cohort study reported by Helmrich and colleagues consisting of a 14-year follow-up survey of 5,990 University of Pennsylvania graduates revealed that, for each 500 kcal increase in energy expenditure due to physical activity, the risk of type 2 DM was decreased by 6%. This report stresses, particularly, the importance of improving vascular resistance and peripheral circulation for amelioration of DM insomuch as 40-60% of DM patients have concurrent hypertension which, together with the DM, promotes diabetic nephropathy, cerebrovascular disorders and coronary artery diseases. PP-LILI elevates peripheral deep-body temperature and stabilizes blood pressure via normalization of sympathetic nerve activity; therefore, PP-LILI may serve as an effective therapy for DM and hypertension even in patients who cannot receive exercise therapy due to motor dysfunction.

**Conclusions**

These obtained data raise the possibility that PP-LILI are useful for the normalization of blood glucose levels by reducing stress hormones such as cortisol, which aggravate DM, and by improving insulin sensitivity, thereby contributing to prevention and treatment of DM.

**References**


Author Disclosure Statement

No competing financial interest exists.

Author Contributions

K.R. wrote manuscript, researched data. K.I. wrote manuscript, researched data. K.K. researched data. Y.N. reviewed/edit-ed manuscript. N.H. contributed to discussion, reviewed/edited manuscript. K.I. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. We certify that this study involving human subjects (the accepted trial registry number: no. 2304) is in accordance with the Helsinki declaration of 1975 as revised in 2000 and that it has been approved by the relevant institutional Ethical Committee. We also certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

[Acknowledgements]

This research was conducted jointly by the medical education Ryotokuji College, Faculty of Health Sciences Ryotokuji University, and Medical Corporation Ryotokuji Group. We thank all the individuals involved in this study. Stress hormone quantification was performed in collaboration with Showa Medical Science.